Lonza and Novartis Jointly to Develop and Manufacture Biologics Products

Lonza says it has entered into a long-term strategic partnership with Novartis for the joint development and manufacture of Novartis's biologics pipeline. R&D activities over the past few years have resulted in a sharp increase in the number of biological compounds, currently accounting for about a quarter of the Novartis development portfolio, Novartis says. The biologics unit of Novartis aims to further grow the biologics pipeline. Lonza will be involved in the development, scale-up and manufacturing of Novartis' biologics pipeline. Lonza will provide...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers